Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy.
BACKGROUND
Renal microvascular injury characterizes thrombotic microangiopathy (TMA). The possibility that angiogenic growth factors may accelerate recovery in TMA has not been studied.


METHODS
TMA was induced in rats by the selective right renal artery perfusion of antiglomerular endothelial cell IgG (30 mg/kg). Twenty-four hours later, rats received vascular endothelial growth factor (VEGF121, 100 microg/kg/day) or vehicle (control) daily until day 14. To evaluate renal function, the unperfused left kidney was removed at day 14, and rats were sacrificed at day 17.


RESULTS
The induction of TMA was associated with loss of glomerular and peritubular capillary endothelial cells and decreased arteriolar density at day 1. Some spontaneous capillary recovery was present by day 17; however, repair was incomplete, and severe tubulointerstitial damage occurred. The lack of complete microvascular recovery was associated with reduced VEGF immunostaining in the outer medulla. VEGF-treated rats had more glomeruli with intact endothelium, less glomerular ischemia (collapsed glomeruli), and greater peritubular capillary density with less peritubular capillary loss. This was associated with less tubulointerstitial fibrosis, less cortical atrophy, and improved renal function.


CONCLUSIONS
VEGF accelerates renal recovery in this experimental model of TMA. These studies suggest that angiogenic growth factors may provide a new therapeutic strategy for diseases associated with endothelial cell injury.
Kim
Y G
YG
Division of Nephrology, University of Washington Medical Center, Seattle, Washington, USA.
Suga
S I
SI
Kang
D H
DH
Jefferson
J A
JA
Mazzali
M
M
Gordon
K L
KL
Matsui
K
K
Breiteneder-Geleff
S
S
Shankland
S J
SJ
Hughes
J
J
Kerjaschki
D
D
Schreiner
G F
GF
Johnson
R J
RJ
D000818:Animals; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy / Q000473:pathology; D007074:Immunoglobulin G / Q000494:pharmacology; D007511:Ischemia / Q000188:drug therapy* / Q000473:pathology; D007678:Kidney Glomerulus / Q000098:blood supply* / Q000276:immunology / Q000503:physiopathology; D008222:Lymphokines / Q000494:pharmacology*; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function; D013927:Thrombosis / Q000188:drug therapy* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007074:Immunoglobulin G; D008222:Lymphokines; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors